GlassScriptPhysician profile
Michael Shabtai
NPI 1942217021
$8,584.69
in general payments reported to CMS, 2019-2025
28 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 90% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,208 · 2020: $794 · 2021: $1,153 · 2022: $999 · 2023: $1,093 · 2024: $958 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,430.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $1,697.10 | 2021-2025 | Xeomin |
| Abbvie INC. | $1,525.87 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,167.00 | 2019-2025 | Xifaxan |
| Merz North America, INC. | $654.11 | 2019-2020 | |
| Amgen INC. | $420.85 | 2019-2021 | |
| Lilly USA, LLC | $371.56 | 2019-2020 | |
| Stryker Corporation | $247.39 | 2024 | Mako, Insignia |
| Novo Nordisk INC | $242.09 | 2025 | Ozempic |
| Indivior INC. | $234.22 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $208.85 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $189.27 | 2021 | |
| Biodelivery Sciences International, INC. | $167.19 | 2019-2020 | |
| Fidia Pharma USA INC. | $165.50 | 2019-2023 | Triluron, Hymovis |
| Biohaven Pharmaceutical Holding Company LTD. | $127.34 | 2022 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $124.99 | 2019 | |
| Depuy Synthes Sales INC. | $123.47 | 2020-2023 | Orthovisc, Monovisc |
| Kowa Pharmaceuticals America, INC. | $121.83 | 2025 | Zoryve |
| Amarin Pharma, INC. | $118.80 | 2020 | |
| Grt US Holding, INC. | $118.08 | 2021-2022 | |
| Penumbra, INC. | $107.90 | 2023 | Penumbra System |
| Spr Therapeutics, INC | $102.51 | 2024 | Sprint Pns System |
| Allergan, INC. | $81.82 | 2019-2021 | |
| Paragon 28, INC. | $64.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.84 | 2021 | |
| Zyla Life Sciences, INC. | $20.82 | 2020 | |
| Averitas Pharma INC. | $20.80 | 2025 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shabtai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.